These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 38254627)

  • 41. Understanding Carbohydrate Metabolism and Insulin Resistance in Acute Intermittent Porphyria.
    Solares I; Jericó D; Córdoba KM; Morales-Conejo M; Ena J; Enríquez de Salamanca R; Fontanellas A
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613492
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypothesis: Metabolic targeting of 5-aminolevulinate synthase by tryptophan and inhibitors of heme utilisation by tryptophan 2,3-dioxygenase as potential therapies of acute hepatic porphyrias.
    Badawy AA
    Med Hypotheses; 2019 Oct; 131():109314. PubMed ID: 31443750
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement.
    Johansson A; Möller C; Fogh J; Harper P
    Mol Med; 2003; 9(9-12):193-9. PubMed ID: 15208740
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cimetidine suppresses chemically induced experimental hepatic porphyria.
    Marcus DL; Nadel H; Lew G; Freedman ML
    Am J Med Sci; 1990 Oct; 300(4):214-7. PubMed ID: 2248274
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The incidence of inherited porphyrias in Europe.
    Elder G; Harper P; Badminton M; Sandberg S; Deybach JC
    J Inherit Metab Dis; 2013 Sep; 36(5):849-57. PubMed ID: 23114748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion.
    Floderus Y; Sardh E; Möller C; Andersson C; Rejkjaer L; Andersson DE; Harper P
    Clin Chem; 2006 Apr; 52(4):701-7. PubMed ID: 16497943
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The hepatic porphyrias.
    Romeo G
    Prog Med Genet; 1980; 4():169-97. PubMed ID: 7003654
    [No Abstract]   [Full Text] [Related]  

  • 48. Results of a pilot study of isoniazid in patients with erythropoietic protoporphyria.
    Parker CJ; Desnick RJ; Bissel MD; Bloomer JR; Singal A; Gouya L; Puy H; Anderson KE; Balwani M; Phillips JD
    Mol Genet Metab; 2019 Nov; 128(3):309-313. PubMed ID: 31395332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver.
    Schmitt C; Lenglet H; Yu A; Delaby C; Benecke A; Lefebvre T; Letteron P; Paradis V; Wahlin S; Sandberg S; Harper P; Sardh E; Sandvik AK; Hov JR; Aarsand AK; Chiche L; Bazille C; Scoazec JY; To-Figueras J; Carrascal M; Abian J; Mirmiran A; Karim Z; Deybach JC; Puy H; Peoc'h K; Manceau H; Gouya L
    J Intern Med; 2018 Jul; 284(1):78-91. PubMed ID: 29498764
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Liver transplantation in the management of porphyria.
    Singal AK; Parker C; Bowden C; Thapar M; Liu L; McGuire BM
    Hepatology; 2014 Sep; 60(3):1082-9. PubMed ID: 24700519
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Givosiran to treat acute porphyria.
    Honor A; Rudnick SR; Bonkovsky HL
    Drugs Today (Barc); 2021 Jan; 57(1):47-59. PubMed ID: 33594389
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias.
    Ramanujam VS; Anderson KE
    Curr Protoc Hum Genet; 2015 Jul; 86():17.20.1-17.20.26. PubMed ID: 26132003
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Erythropoietic protoporphyria: case reports for clinical and therapeutic hints.
    Tumminelli C; Burlo F; Pastore S; Severini GM; Berti I; Marchini S; Zanon D; De Martino E; Tommasini A
    Ital J Pediatr; 2023 Nov; 49(1):156. PubMed ID: 37996925
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria.
    Harper P; Wahlin S
    Curr Treat Options Gastroenterol; 2007 Dec; 10(6):444-55. PubMed ID: 18221605
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cimetidine in the treatment of porphyria cutanea tarda.
    Horie Y; Tanaka K; Okano J; Ohgi N; Kawasaki H; Yamamoto S; Kondo M; Sassa S
    Intern Med; 1996 Sep; 35(9):717-9. PubMed ID: 8915698
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development and validation of diagnostic algorithms for the laboratory diagnosis of porphyrias.
    Lefever S; Peersman N; Meersseman W; Cassiman D; Vermeersch P
    J Inherit Metab Dis; 2022 Nov; 45(6):1151-1162. PubMed ID: 36053909
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria.
    Yin Z; Wahlin S; Ellis EC; Harper P; Ericzon BG; Nowak G
    Cell Transplant; 2014; 23(9):1153-62. PubMed ID: 23582197
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of cimetidine on delta-aminolevulinic acid synthase and microsomal heme oxygenase in rat liver.
    Marcus DL; Halbrecht JL; Bourque AL; Lew G; Nadel H; Freedman ML
    Biochem Pharmacol; 1984 Jul; 33(13):2005-8. PubMed ID: 6547609
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Erythropoietic and hepatic porphyrias.
    Gross U; Hoffmann GF; Doss MO
    J Inherit Metab Dis; 2000 Nov; 23(7):641-61. PubMed ID: 11117426
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria.
    Sardh E; Harper P; Balwani M; Stein P; Rees D; Bissell DM; Desnick R; Parker C; Phillips J; Bonkovsky HL; Vassiliou D; Penz C; Chan-Daniels A; He Q; Querbes W; Fitzgerald K; Kim JB; Garg P; Vaishnaw A; Simon AR; Anderson KE
    N Engl J Med; 2019 Feb; 380(6):549-558. PubMed ID: 30726693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.